Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 1129-1138

  Gelber, Shari E ^a   Brent, Elyssa ^a   Redecha, Patricia ^a   Perino, Giorgio ^b   Tomlinson, Stephen ^c,d   Davisson, Robin L ^a,e   Salmon, Jane E ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^e Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; COMPLEMENT; COMPLEMENT INHIBITOR; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL SELECTION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DEFECTIVE PLACENTATION; DISEASE ASSOCIATION; FEMALE; FETUS DEATH; FETUS DEVELOPMENT; FETUS WASTAGE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL DEPLETION; NONHUMAN; PLACENTA DEVELOPMENT; PLACENTA DISORDER; PLACENTA INSUFFICIENCY; PLACENTA WEIGHT; PREGNANCY DISORDER; PREGNANCY LOSS; PREGNANCY OUTCOME; PRIORITY JOURNAL; SPIRAL ARTERY REMODELING; VASCULAR REMODELING; ABORTION, SPONTANEOUS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; INTRAUTERINE GROWTH RETARDATION; METABOLISM; PLACENTA; PLACENTAL INSUFFICIENCY; PREGNANCY; REPRODUCTION; TROPHOBLAST;

ABORTION, SPONTANEOUS; ANIMALS; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; HUMANS; IMMUNITY, INNATE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NEUTROPHILS; PLACENTA; PLACENTAL INSUFFICIENCY; PLACENTATION; PREGNANCY; TROPHOBLASTS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937717879     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402220     Document Type: Article

References (62)

1. Roberts, D. J., and M. D. Post. 2008. The placenta in pre-eclampsia and intrauterine growth restriction. J. Clin. Pathol. 61: 1254-1260.
2. Brosens, I., R. Pijnenborg, L. Vercruysse, and R. Romero. 2011. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am. J. Obstet. Gynecol. 204: 193-201.
3. Li, M., and S. J. Huang. 2009. Innate immunity, coagulation and placenta-related adverse pregnancy outcomes. Thromb. Res. 124: 656-662.
4. Hahn, S., A. K. Gupta, C. Troeger, C. Rusterholz, and W. Holzgreve. 2006. Disturbances in placental immunology: ready for therapeutic interventions? Springer Semin. Immunopathol. 27: 477-493.
5. Qing, X., P. B. Redecha, M. A. Burmeister, S. Tomlinson, V. D. D'Agati, R. L. Davisson, and J. E. Salmon. 2011. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 79: 331-339.
6. Redecha, P., R. Tilley, M. Tencati, J. E. Salmon, D. Kirchhofer, N. Mackman, and G. Girardi. 2007. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110: 2423-2431.
7. Renaud, S. J., T. Cotechini, J. S. Quirt, S. K. Macdonald-Goodfellow, M. Othman, and C. H. Graham. 2011. Spontaneous pregnancy loss mediated by abnormal maternal inflammation in rats is linked to deficient uteroplacental perfusion. J. Immunol. 186: 1799-1808.
8. Scharfe-Nugent, A., S. C. Corr, S. B. Carpenter, L. Keogh, B. Doyle, C. Martin, K. A. Fitzgerald, S. Daly, J. J. O'Leary, and L. A. J. O'Neill. 2012. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J. Immunol. 188: 5706-5712.
9. Girardi, G., D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon. 2006. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203: 2165-2175.
10. Wang, W., R. A. Irani, Y. Zhang, S. M. Ramin, S. C. Blackwell, L. Tao, R. E. Kellems, and Y. Xia. 2012. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 60: 712-721.
11. Holers, V. M., G. Girardi, L. Mo, J. M. Guthridge, H. Molina, S. S. Pierangeli, R. Espinola, L. E. Xiaowei, D. Mao, C. G. Vialpando, and J. E. Salmon. 2002. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195: 211-220.
12. Carpentier, P. A., A. L. Dingman, and T. D. Palmer. 2011. Placental TNF-A signaling in illness-induced complications of pregnancy. Am. J. Pathol. 178: 2802-2810.
13. Murphy, S. P., L. D. Fast, N. N. Hanna, and S. Sharma. 2005. Uterine NK cells mediate inflammation-induced fetal demise in IL-10-null mice. J. Immunol. 175: 4084-4090.
14. Samstein, R. M., S. Z. Josefowicz, A. Arvey, P. M. Treuting, and A. Y. Rudensky. 2012. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 150: 29-38.
15. Lee, A. J., N. Kandiah, K. Karimi, D. A. Clark, and A. A. Ashkar. 2013. Interleukin-15 is required for maximal lipopolysaccharide-induced abortion. J. Leukoc. Biol. 93: 905-912.
16. Murphy, S. P., N. N. Hanna, L. D. Fast, S. K. Shaw, G. Berg, J. F. Padbury, R. Romero, and S. Sharma. 2009. Evidence for participation of uterine natural killer cells in the mechanisms responsible for spontaneous preterm labor and delivery. Am. J. Obstet. Gynecol. 200: 308.e1-9.
17. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.
18. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
19. Pangburn, M. K., V. P. Ferreira, and C. Cortes. 2008. Discrimination between host and pathogens by the complement system. Vaccine 26(Suppl. 8): I15-I21.
20. Lynch, A. M., J. R. Murphy, T. Byers, R. S. Gibbs, M. C. Neville, P. C. Giclas, J. E. Salmon, and V. M. Holers. 2008. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 198: 385.e1-9.
21. Lynch, A. M., and J. E. Salmon. 2010. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 31: 561-567.
22. Buurma, A., D. Cohen, K. Veraar, D. Schonkeren, F. H. Claas, J. A. Bruijn, K. W. Bloemenkamp, and H. J. Baelde. 2012. Preeclampsia is characterized by placental complement dysregulation. Hypertension 60: 1332-1337.
23. Bulla, R., F. Bossi, C. Agostinis, O. Radillo, F. Colombo, F. De Seta, and F. Tedesco. 2009. Complement production by trophoblast cells at the fetomaternal interface. J. Reprod. Immunol. 82: 119-125.
24. Xu, C., D. Mao, V. M. Holers, B. Palanca, A. M. Cheng, and H. Molina. 2000. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287: 498-501.
25. Wetsel, R. A. 1995. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 7: 48-53.
26. Camous, L., L. Roumenina, S. Bigot, S. Brachemi, V. Frémeaux-Bacchi, P. Lesavre, and L. Halbwachs-Mecarelli. 2011. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117: 1340-1349.
27. Girardi, G., J. Berman, P. Redecha, L. Spruce, J. M. Thurman, D. Kraus, T. J. Hollmann, P. Casali, M. C. Caroll, R. A. Wetsel, et al. 2003. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112: 1644-1654.
28. Redecha, P., C.-W. Franzke, W. Ruf, N. Mackman, and G. Girardi. 2008. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J. Clin. Invest. 118: 3453-3461.
29. Gupta, A. K., M. B. Joshi, M. Philippova, P. Erne, P. Hasler, S. Hahn, and T. J. Resink. 2010. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett. 584: 3193-3197.
30. Hunt, J. S., H. L. Chen, and L. Miller. 1996. Tumor necrosis factors: pivotal components of pregnancy? Biol. Reprod. 54: 554-562.
31. Haider, S., and M. Knöfler. 2009. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta 30: 111-123.
32. Otun, H. A., G. E. Lash, B. A. Innes, J. N. Bulmer, K. Naruse, T. Hannon, R. F. Searle, and S. C. Robson. 2011. Effect of tumour necrosis factor-A in combination with interferon-g on first trimester extravillous trophoblast invasion. J. Reprod. Immunol. 88: 1-11.
33. Berman, J., G. Girardi, and J. E. Salmon. 2005. TNF-A is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J. Immunol. 174: 485-490.
34. Cotechini, T., M. Komisarenko, A. Sperou, S. Macdonald-Goodfellow, M. A. Adams, and C. H. Graham. 2014. Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia. J. Exp. Med. 211: 165-179.
35. Holcberg, G., M. Huleihel, O. Sapir, M. Katz, M. Tsadkin, B. Furman, M. Mazor, and L. Myatt. 2001. Increased production of tumor necrosis factoralpha TNF-A by IUGR human placentae. Eur. J. Obstet. Gynecol. Reprod. Biol. 94: 69-72.
36. Pijnenborg, R., P. J. McLaughlin, L. Vercruysse, M. Hanssens, P. M. Johnson, J. C. Keith, Jr., and F. A. Van Assche. 1998. Immunolocalization of tumour necrosis factor-A (TNF-A) in the placental bed of normotensive and hypertensive human pregnancies. Placenta 19: 231-239.
37. Kupferminc, M. J., A. M. Peaceman, T. R. Wigton, K. A. Rehnberg, and M. L. Socol. 1994. Tumor necrosis factor-A is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am. J. Obstet. Gynecol. 170: 1752-1757.
38. Davisson, R. L., D. S. Hoffmann, G. M. Butz, G. Aldape, G. Schlager, D. C. Merrill, S. Sethi, R. M. Weiss, and J. N. Bates. 2002. Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension 39: 337-342.
39. Dokras, A., D. S. Hoffmann, J. S. Eastvold, M. F. Kienzle, L. M. Gruman, P. A. Kirby, R. M. Weiss, and R. L. Davisson. 2006. Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia. Biol. Reprod. 75: 899-907.
40. Schlager, G. 1994. Biometrical genetic analysis of blood pressure level in the genetically hypertensive mouse. Clin. Exp. Hypertens. 16: 809-824.
41. Atkinson, C., H. Song, B. Lu, F. Qiao, T. A. Burns, V. M. Holers, G. C. Tsokos, and S. Tomlinson. 2005. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 115: 2444-2453.
42. Huang, Y., F. Qiao, C. Atkinson, V. M. Holers, and S. Tomlinson. 2008. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181: 8068-8076.
43. Banda, N. K., J. M. Thurman, D. Kraus, A. Wood, M. C. Carroll, W. P. Arend, and V. M. Holers. 2006. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collageninduced arthritis. J. Immunol. 177: 1904-1912.
44. Graham, C. H., T. S. Hawley, R. G. Hawley, J. R. MacDougall, R. S. Kerbel, N. Khoo, and P. K. Lala. 1993. Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp. Cell Res. 206: 204-211.
45. Pricop, L., J. Gokhale, P. Redecha, S. C. Ng, and J. E. Salmon. 1999. Reactive oxygen intermediates enhance Fcg receptor signaling and amplify phagocytic capacity. J. Immunol. 162: 7041-7048.
46. Wang, Y., Y. Gu, L. Philibert, and M. J. Lucas. 2001. Neutrophil activation induced by placental factors in normal and pre-eclamptic pregnancies in vitro. Placenta 22: 560-565.
47. Butterworth, B. H., I. A. Greer, W. A. Liston, N. G. Haddad, and T. A. Johnston. 1991. Immunocytochemical localization of neutrophil elastase in term placenta decidua and myometrium in pregnancy-induced hypertension. Br. J. Obstet. Gynaecol. 98: 929-933.
48. McMaster, M. T., S. K. Dey, and G. K. Andrews. 1993. Association of monocytes and neutrophils with early events of blastocyst implantation in mice. J. Reprod. Fertil. 99: 561-569.
49. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83: 64-70.
50. Woods, A. K., D. S. Hoffmann, C. J. Weydert, S. D. Butler, Y. Zhou, R. V. Sharma, and R. L. Davisson. 2011. Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 57: 94-102.
51. Salmon, J. E., C. Heuser, M. Triebwasser, M. K. Liszewski, D. Kavanagh, L. Roumenina, D. W. Branch, T. Goodship, V. Frémeaux-Bacchi, and J. P. Atkinson. 2011. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 8: e1001013.
52. Lynch, A. M., R. S. Gibbs, J. R. Murphy, P. C. Giclas, J. E. Salmon, and V. M. Holers. 2011. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet. Gynecol. 117: 75-83.
53. Banda, N. K., B. Levitt, M. J. Glogowska, J. M. Thurman, K. Takahashi, G. L. Stahl, S. Tomlinson, W. P. Arend, and V. M. Holers. 2009. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 183: 5928-5937.
54. Sekine, H., T. T. H. Kinser, F. Qiao, E. Martinez, E. Paulling, P. Ruiz, G. S. Gilkeson, and S. Tomlinson. 2011. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 63: 1076-1085.
55. Song, H., F. Qiao, C. Atkinson, V. M. Holers, and S. Tomlinson. 2007. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J. Immunol. 179: 7860-7867.
56. Gasperini, S., F. Calzetti, M. P. Russo, M. De Gironcoli, and M. A. Cassatella. 1995. Regulation of GRO alpha production in human granulocytes. J. Inflamm. 45: 143-151.
57. Mulla, M. J., J. J. Brosens, L. W. Chamley, I. Giles, C. Pericleous, A. Rahman, S. K. Joyce, B. Panda, M. J. Paidas, and V. M. Abrahams. 2009. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am. J. Reprod. Immunol. 62: 96-111.
58. Xu, B., S. Nakhla, A. Makris, and A. Hennessy. 2011. TNF-A inhibits trophoblast integration into endothelial cellular networks. Placenta 32: 241-246.
59. Renaud, S. J., R. Sullivan, and C. H. Graham. 2009. Tumour necrosis factor alpha stimulates the production of monocyte chemoattractants by extravillous trophoblast cells via differential activation of MAPK pathways. Placenta 30: 313-319.
60. Maynard, S. E., J.-Y. Min, J. Merchan, K.-H. Lim, J. Li, S. Mondal, T. A. Libermann, J. P. Morgan, F. W. Sellke, I. E. Stillman, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111: 649-658.
61. Levine, R. J., S. E. Maynard, C. Qian, K.-H. Lim, L. J. England, K. F. Yu, E. F. Schisterman, R. Thadhani, B. P. Sachs, F. H. Epstein, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350: 672-683.
62. LaMarca, B. D., M. J. Ryan, J. S. Gilbert, S. R. Murphy, and J. P. Granger. 2007. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr. Hypertens. Rep. 9: 480-485.